Issue |
BIO Web Conf.
Volume 154, 2025
15th International Conference on Global Resource Conservation (ICGRC 2024) in conjunction with the 1st International Conference on Jamu and Alternative Medicine (ICJAM 2024)
|
|
---|---|---|
Article Number | 02009 | |
Number of page(s) | 10 | |
Section | Biotechnology and Bioprospecting | |
DOI | https://doi.org/10.1051/bioconf/202515402009 | |
Published online | 28 January 2025 |
Hypoglycemic activity of brown seaweed (Sargassum plagiophyllum) kombucha bioactive compound in rat model type-2 of diabetes
1 Departement of Food Science and Biotechnology, Faculty of Agricultural Technology, Brawijaya University, Malang, Indonesia.
2 Department of Fisheries and Marine Resources Management, Faculty of Fisheries and Marine Science, Brawijaya University, Malang, Indonesia.
* Corresponding author: afarispriambodo@student.ub.ac.id
Hyperglycemia is a condition of increased blood glucose with out of normal limits criteria associated with diabetes mellitus. Uncontrolled hyperglycemia is one of the causes of complications in diabetes mellitus sufferers. Sargassum plagiophyllum is one of brown seaweed that contains many bioactive compounds which are useful as hypoglycemic agents. The kombucha fermentation method is used to reduce structural complexity, thereby increasing the bioavailability of bioactives. This study aims to evaluate the administration of S. plagiophyllum kombucha (SK) to the blood profile of type 2 diabetes mellitus (DM2) rats treated with a 21% highfructose diet (HFD) with normal feed. S. plagiophyllum was obtained from Talango, Sumenep, Madura Island, East Java Province. 2-month-old male Rattus norvegicus was used as a model animal. The study consisted of 5 groups, including negative control, positive control (DM2), DM2 + SK 1.5 mL/250 g bw once a day, DM2 + SK 1.5 mL/250 g bw twice a day, and DM2 + SK 1, 5 mL/250 g bw three times a day. Animal model research was carried out for 2 months. The study’s conclusion shows that S. plagiophyllum kombucha has bioactive compounds as hypoglycemic agents and contributes to improving body weight, fasting blood glucose (FBG), lipid profiles, insulin, and MDA in type-2 diabetes rats model.
© The Authors, published by EDP Sciences, 2025
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.